Basal cell carcinoma - I-Basal Cell Carcinoma
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Izilonda ezinezilonda ezithinta isikhumba sekhala kumuntu osekhulile zivame ukutholakala njenge-I-Basal Cell Carcinoma (Basal cell carcinoma). Ikhala liyindawo evamile yokwenzeka kwalolu hlobo lomdlavuza wesikhumba.
I- I-Basal Cell Carcinoma (Basal cell carcinoma) ingase ibonakale enemingcele engavamile kanye nezilonda.
I-Basal Cell Carcinoma (Basal cell carcinoma) kungenziwa iphutha nensumpa.
References
Basal cell carcinoma (BCC) wuhlobo oluvame kakhulu lomdlavuza wesikhumba. Ukuchayeka elangeni kuyimbangela enkulu. Cishe wonke amacala e-BCC abonisa ukusayinda kwe-Hedgehog okusebenzayo kakhulu ekuhlaziyweni kwamangqamuzana. Izindlela zokwelapha ezihlukene ziyatholakala futhi zikhethwa ngokusekelwe engozini yokuphinda, ukubaluleka kokulondolozwa kwezicubu, okuthandwa yisiguli, kanye nezinga lesifo.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas wuhlobo oluvame kakhulu lomdlavuza wesikhumba kubantu abadala abanebala elimhlophe abaneminyaka engu-50 nangaphezulu. Inani labo liyanda emhlabeni wonke, ikakhulukazi ngenxa yokuchayeka elangeni. Izimo ezithile zofuzo zingenza abantu bathambekele ekubeni nalo mdlavuza besebancane. Basal cell carcinomas ziyahlukahluka ngokuqina, kusukela ezilonda ezilapheka kalula ezingaphezulu noma ezinamaqhuqhuva kuye kweziningi kakhulu ezidinga ingxoxo emaqenjini ezokwelapha akhethekile. Ukubikezela kuncike emathubeni okuthi umdlavuza ubuye noma amandla awo okulimaza izicubu eziseduze. Ukuhlinzwa kuwukwelashwa okujwayelekile ezimeni eziningi, okuqinisekisa ukususwa okunembile kanye namathuba aphansi okuphinda kwenzeke. Izindlela ezincane ezihlaselayo zingaphatha ngempumelelo izilonda ezingaphezulu.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ukwelashwa okuyinhloko kwe-BCC ukuhlinzwa. Nge-BCC enobungozi obukhulu noma ephindaphindayo, ikakhulukazi ezindaweni ezibucayi, kunconywa ukuhlinzwa okulawulwa nge-micrographically. Iziguli ezine-BCC ekha phezulu enengozi ephansi zingase zicabangele ukwelashwa kwezihloko noma izindlela ezilimazayo. Ukwelapha nge-Photodynamic kusebenza kahle kuma-BCC angamanodula angenabungozi obuncane. Ku-BCC ethuthukisiwe yasendaweni noma ene-metastatic, ama-Hedgehog inhibitors (vismodegib, sonidegib) ayanconywa. Uma kukhona ukuqhubekela phambili kwesifo noma ukungabekezelelani kuma-Hedgehog inhibitors, i-immunotherapy ene- anti-PD1 antibody (cemiplimab) ingacatshangelwa. I-Radiotherapy iyindlela enhle ezigulini ezingakwazi ukuhlinzwa, ikakhulukazi iziguli ezindala. I-Electrochemotherapy ingacatshangelwa uma ukuhlinzwa noma ukwelashwa nge-radiotherapy kungeyona inketho.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Izinto eziyingozi zihlanganisa ukuchayeka ekukhanyeni kwe-ultraviolet, ukwelapha ngemisebe, ukuchayeka isikhathi eside ku-arsenic kanye nokusebenza kabi kwesistimu yokuzivikela komzimba (isb. ukufakelwa izitho zomzimba). Ukuchayeka ekukhanyeni kwe-UV ebuntwaneni kuyingozi kakhulu.
Ngemuva kokuxilongwa nge-biopsy, ukwelashwa kuvame ukususwa ngokuhlinzwa. Lokhu kungaba ngokusikwa okulula uma umdlavuza umncane; Uma umdlavuza ungemncane, ukuhlinzwa kwe-Mohs ngokuvamile kuyanconywa.
I-basal cell carcinoma yenza okungenani ama-32% awo wonke umdlavuza emhlabeni jikelele. Emidlavuza yesikhumba ngaphandle kwe-melanoma, cishe ama-80% awomdlavuza we-basal-cell. E-United States, cishe amaphesenti angama-35 abesilisa abamhlophe kanye nama-25% abesifazane abamhlophe bahlaselwa yi-basal cell carcinoma esikhathini esithile ekuphileni kwabo.
○ Ukuxilongwa Nokwelashwa
#Dermoscopy
#Skin biopsy
#Mohs surgery